
Figure 1


Hyg
(-ATG)
pA
bla
pA
Lnk
F
SV40
HC1
GS
Ex2
Int
Ex1
F5
hCMV
Ex2
hCMV
pA
LC1
Int
Ex1




Figure 2




Figure 3

Figure 4




F-Lnk
bla L
GS
F5
LC1
HC1
Hyg
bla R
SV TK
SV PAC
F5
F
bla
bla L
GS
F5
TK
PAC
bla R
SV
SV
F-Lnk
Hyg

Figure 5


F-Lnk
bla L
GS
F5
SV TK
SV PAC
Hyg
Bla R
F5
LC2
HC2
SV
ATG-F
bla
bla L
GS
F5
LC2
HC2
SV
bla R
ATG-F
-Lnk
-Hyg



Antibody Concentration (mg/L)
400
350
300
250
200
150
100
50
0
Random
SSI Round 1
SSI Round 2
SSI Round 3

Figure 6



3'
integration
site
5'
integration
Site
Exon
39
38
37-36
35-32
31-29
28-27
1750 kb
1755 kb
1760 kb

Figure 7




Figure 8



A
10E9
0 - 100
5' seq
HC (214 bp deletion)
Hyg (-ATG)
BlaL
GS cDNA
HSV-TK
PAC
Hyg (-ATG)
BlaL
3' seq
F
HC
hyg
BlaR/L
GS
F5
TK
PAC
hyg
BlaR
5'
3'
B
HC hyg Bla R/L GS
TK PAC hyg Bla R/L GS
TK PAC hyg BlaR
PmlI
8685 bp
PmlI
BmgBI
7428 bp
BmgBI
C I II C I II
12.2
10.2
8.1
6.1
5.1
4.1
3.1
kb
Bmg.
Pml.
TK

Figure 9




Figure 10



CellLine1 |0 - 100 |
CellLine2 |0 - 100 |
CellLine3 |0 - 100 |
CellLine4 |0 - 100 |
HC with 214bp Deletion from 5'
BlaR
Myo-LC
Myo-HC
Hyg
BlaL
GS cDNA
Tk
ACTGTGGGACCCTCATTTCAGACTCTACT A
TGTGGGACCCTCATTTCAGACTCTACT A
TTCAGACTCTACT A
CTACT A
A
T GTCTAGGACTCTGGC
T GTCTAGGACTCTGGCC
C

Figure 11



Cell line 1
Cell line 2
Cell line 3
Cell line 4
|0 - 400000|
|0 - 400000|
|0 - 400000|
|0 - 400000|
IE promoter
5' UTR
Myo LC
pA
hCMV-MIE promoter
5' UTR
Myo HC
5' UTR
pA

Figure 12